TAK-653 vs PE-22-28
Side-by-side comparison of TAK-653 and PE-22-28: mechanism, half-life, dose range, safety profile, and vendor pricing.
Price snapshot
TAK-653
PE-22-28
TAK-653
TAK-653 is a novel positive allosteric modulator (PAM) of AMPA-type glutamate receptors developed by Takeda Pharmaceuticals. It enhances glutamatergic neurotransmission without directly activating the receptor, offering…
Lowest listed price: $79.99 across 1 listing
Full TAK-653 profilePE-22-28
PE-22-28 is a synthetic seven-amino-acid peptide (sequence PAGASRLLLLTGEIDLP derivative, commonly truncated to PE-22-28 as shorthand for "position 22-28" within the parent humanin-family sequence) that was designed as an…
Lowest listed price: $49.99 across 1 listing
Full PE-22-28 profileSide-by-side comparison
| Attribute | TAK-653 | PE-22-28 |
|---|---|---|
| Category | Nootropics | Nootropics |
| Research Stage | Phase II Clinical Trials | Preclinical |
| Mechanism of Action | TAK-653 acts as a positive allosteric modulator (PAM) of AMPA receptors, binding to a site distinct from the glutamate binding site. It increases the receptor's sensitivity to glutamate, improving excitatory postsynaptic currents (EPSCs) and promoting… | PE-22-28 is a synthetic 7-amino-acid peptide (sequence GVSWGLR) and a shortened analog of spadin. Its proposed mechanism is inhibition of the TREK-1 (TWIK-related K+) channel, a two-pore-domain potassium channel (K2P2.1 / KCNK2) implicated in mood regulation.… |
| Half-Life | 6-10 hours (estimated) | Not characterized in humans. As a small 7-amino-acid peptide a short plasma half-life is expected; in mice the parent peptide spadin lost antidepressant activity by about 7 hours after a single dose, while modified analogs (e.g., G/A-PE 22-28) extended the behavioral effect to roughly 21-23 hours [PMID:28955242]. |
| Typical Dose Range | 0.1 mg - 6 mg | 250-2000 mcg subcutaneous per dose (empirical research-chemical community range; no clinically validated human dose exists; effective preclinical rodent doses were far lower, ~3 mcg/kg). |
| Dosing Frequency | Once daily | Once daily or every other day (research-chemical community protocols; no validated clinical dosing schedule). |
| Administration | Oral | — |
| Side Effects | Headache, mild nausea, insomnia (if taken late in day), potential overstimulation at higher doses. Seizure risk at supratherapeutic doses due to glutamatergic mechanism. Mild anxiety or agitation reported in some users. | No human side-effect data exist for PE-22-28 because it has never been tested in people. What can be said comes from rodent studies of PE-22-28, spadin and their analogs, plus general considerations for injected research peptides. In the preclinical work, the… |
| Molecular Weight | 282.27 | 773.9 g/mol |
| Common Vial Sizes | — | — |
Price tracking
Price History
2 data pointsTAK-653: potential benefits
- Cognitive enhancement and improved learning
- Antidepressant effects (treatment-resistant depression)
- Enhanced synaptic plasticity and LTP
- Increased BDNF expression
- Improved working memory and executive function
- Potential neuroprotective properties
PE-22-28: potential benefits
- Antidepressant-like effects in rodent models of depression (preclinical only)
- Potent, selective inhibition of the TREK-1 (K2P2.1) potassium channel (IC50 ~0.12 nM)
- Rapid-onset (~4-day) antidepressant profile in animals, unlike the multi-week lag of SSRIs
- Increased hippocampal neurogenesis in mice
- Increased cortical synaptogenesis (PSD-95) and BDNF expression in preclinical studies
- No human-validated benefits; not approved for any use (research use only)
Frequently asked
What's the difference between TAK-653 and PE-22-28?
TAK-653 is a nootropics that tak-653 acts as a positive allosteric modulator (pam) of ampa receptors, binding to a site distinct from the glutamate binding site. it increases the receptor's sensitivity to…. PE-22-28 is a nootropics that pe-22-28 is a synthetic 7-amino-acid peptide (sequence gvswglr) and a shortened analog of spadin. its proposed mechanism is inhibition of the trek-1 (twik-related k+) channel, a…. The two differ in mechanism, half-life (6-10 hours (estimated) vs Not characterized in humans. As a small 7-amino-acid peptide a short plasma half-life is expected; in mice the parent peptide spadin lost antidepressant activity by about 7 hours after a single dose, while modified analogs (e.g., G/A-PE 22-28) extended the behavioral effect to roughly 21-23 hours [PMID:28955242].), and typical dose range.
Which has the longer half-life, TAK-653 or PE-22-28?
TAK-653 has a half-life of 6-10 hours (estimated). PE-22-28 has a half-life of Not characterized in humans. As a small 7-amino-acid peptide a short plasma half-life is expected; in mice the parent peptide spadin lost antidepressant activity by about 7 hours after a single dose, while modified analogs (e.g., G/A-PE 22-28) extended the behavioral effect to roughly 21-23 hours [PMID:28955242].. Longer half-lives generally mean less frequent dosing but slower on/off kinetics.
Which is cheaper, TAK-653 or PE-22-28?
Lowest listed price on BodyHackGuide: TAK-653 from $79.99, PE-22-28 from $49.99. Prices are pulled from the vendor listings tracked on BHG and change frequently. See the compare tables on each compound page for the current set of offers.
Can you stack TAK-653 and PE-22-28?
Few pairs of research compounds have been tested together in people, so for most pairs no trial shows whether combining them is safe or adds anything. Each compound's page lists its side effects and the interactions in our record, and the table on this page puts their side effects side by side.
See current vendor prices
Listings from the vendors we track. Prices change often, so check the vendor before you buy.
Before you buy TAK-653 or PE-22-28
Check the vendor trust score. Every supplier we track is rated 0-100 on COA verification, payment transparency, shipping, reviews, and listings: one published, reproducible methodology, applied to every vendor.
Related comparisons
Research use only. BodyHackGuide is a research and price-comparison reference. The compounds discussed on this page are not approved by the FDA for human consumption and are sold strictly for laboratory research. Prices shown are pulled from vendor listings tracked on BHG and are subject to change. Every vendor is ranked on the same public, reproducible methodology. See editorial standards and affiliate disclosure.